Risk Partners Life Sciences Roundtable 2025, thank you very much! 

Contact us

We congratulate Formycon AG on its successful uplisting to the Prime Standard of Deutsche Börse on November 12, 2024!

Welcome to the Prime Standard league: A new champion of life sciences and biosimilars has successfully made the step from the scale segment. We proudly congratulate Enno Spillner, Dr. Caroline Redeker, Daniel Marquard and the entire Formycon AG team on this great success and another important milestone on their way to becoming a global champion in the biosimilars sector!

Formycon AG specializes in the development of high-quality biosimilars, which represent a cost-effective alternative to original biopharmaceutical preparations. The company demonstrates its innovative strength particularly in the field of follow-on molecules and has successfully positioned itself as one of the leading suppliers of biosimilars. With its expertise in research and development, Formycon creates access to cutting-edge biopharmaceutical products that benefit patients worldwide and has now also attracted increasing interest from international investors. As a result, the company has now been listed in the Prime Standard.  

Risk Partners acted as Capital Markets Insurance Advisor in this transaction. Our team, consisting of Florian, Franziska and Björn, supported Formycon AG during the successful uplisting process from the Scale to the Prime Standard of the Frankfurt Stock Exchange on November 12, 2024.

We are particularly pleased to contribute our specialization and expertise as an insurance broker for life sciences and capital market transactions and to accompany a "neighbor" from the Planegg/Martinsried region.

Special thanks also go to our co-broker team at Dr. Ellwanger & Kramm GmbH & Co. KG, in particular Gregor Klingeler and Frieder Lang, for the trust they have placed in us and the great cooperation. If you have a similar project in mind and would appreciate our support, please do not hesitate to contact us about the added value of RP4brokers. 

Also read our other blog posts
Being Public

Risk Partners supports successful uplisting of Formycon AG to the Prime Standard

Congratulations to Formycon AG on its successful uplisting to the Prime Standard of Deutsche Börse on November 12, 2024! Welcome to the Prime Standard league: A new champion of life sciences and biosimilars has successfully made the step from the Scale segment. We proudly congratulate Enno Spillner, Dr. Caroline Redeker, Daniel Marquard and the entire Formycon AG team on this great success and another important milestone on their way to becoming a global champion in the field of biosimilars! Formycon AG has focused on

Read more "
November 14, 2024
Venture Capital

We provide information on liability risks for VC funds in the VC Magazine

In December, we were asked by VC-Magazin whether we could provide insights into liability and risk management issues relating to venture capital funds. With pleasure! Together with the team, Florian not only provided insights into current challenges, but also suggested practical solutions to effectively minimize and sensibly transfer the risks of a VC fund. In the VC Magazine article, you will therefore find: added value of customized insurance concepts for VC funds (focus: D&O/E&O insurance #Moonshot Protect), key measures for risk prevention (learning curve from our claims world), indemnifying contractual provisions as a preventive measure, and

Read more "
January 26, 2024
Management

Research breakdown at Stockholm's Karolinska Institute: A cooling failure destroys cell cultures from decades of research

Research mishap at Stockholm's Karolinska Institute: A cooling failure destroys cell cultures from decades of research - can you insure against it? An incident that threatens your very existence, but which we would like to shed some light on from the perspective of an insurance broker specializing in life sciences. What happened? A cooling system at the Karolinska Institute in Stockholm, Sweden's most important medical research center, failed for five days. Biological material that had been collected over 30 years and, according to the institute, was unique in the world, was destroyed as a result. The material was stored in deep-freeze tanks in which the temperature

Read more "
June 7, 2024
Being Public

New SEC Ruling: Transatlantic convergence in dealing with cyber security incidents

Foreign Filers / Private Issuers watch out! 2023 brought further harmonization of European and US standards for cyber incident reporting. According to the SEC Ruling, all companies listed on the US stock exchange are now required to publicly report significant data security incidents to the SEC within four working days. In addition, they must outline in their annual report (10-K) their procedures for identifying and addressing material cybersecurity risks, including the role of the board of directors. Note: This rule also applies to foreign private issuers (e.g., German companies that issue a

Read more "
January 17, 2024
Life Sciences

Atrialis GmbH - experts in clinical trial insurance

Atrialis GmbH - experts in clinical trial insurance & Risk Partners will play in the same team in the future. LifeSciences - Leading risk concepts for leading science! Under this guiding principle, we have been able to advise innovative companies from the biotechnology, pharmaceutical and medical device sectors comprehensively on risk issues for many years and support them with suitable insurance solutions in all growth and study phases, from foundation to IPO and beyond (e.g. insuring a clinical trial). Together with my team at Risk Partners GmbH, we would like to continue our focus, our passion

Read more "
October 31, 2023
Being Public

Whistleblower Protection Act

Whistleblower Protection Act ... is now in force. Hey #VCs, do you already have a system in place for safe #whistleblowing? And what about insurance cover in your D&O insurance? One month ago today, the German Whistleblower Protection Act came into force. Since July 2, 2023, not only companies with more than 50 employees, but also fund managers or ManCos (capital management companies pursuant to Section 17 (1) of the German Investment Code) are obliged to set up and operate a whistleblower system, regardless (!) of the number of employees. As of December 2

Read more "
October 31, 2023